Orbactiv Approved for Drug-Resistant Skin Infections
The drug is sanctioned to treat methicillin-resistant Staphylococcus aureus (MRSA) and other acute bacterial skin infections. It's the third such drug approved in 2014, following May approval of Dalvance (dalbavancin) and June approval of Sivextro (tedizolid), the FDA said.
Orbactiv's safety and effectiveness were evaluated in two clinical studies involving almost 2,000 adults. The most common side effects included headache, nausea, vomiting, skin abscesses on the arms and legs, and diarrhea.
The drug's label will include a boxed warning that it could interact with the blood-thinning medication warfarin, the agency said.
Orbactiv is marketed by The Medicines Company, based in Parsippany, N.J.
More information
The FDA has more about this approval.
Hochul, Blakeman poll, home heating oil prices rise, and deer population explodes. Here's a look at some of the exclusive stories you may have missed this week on NewsdayTV.
Hochul, Blakeman poll, home heating oil prices rise, and deer population explodes. Here's a look at some of the exclusive stories you may have missed this week on NewsdayTV.
